Leveraging our expertise in viral oncology and tumor immunology, we are actively translating these molecular discoveries into next-generation therapies. A major focus of our future directions involves developing targeted interventions—such as small-molecule autophagy inhibitors (e.g., targeting the ULK1 complex) and engineered viral vector delivery systems—to prevent MHC-I degradation. By combining these targeted approaches with existing immunotherapies, we aim to bridge the gap between basic virology and clinical oncology, establishing highly effective treatments for patients with HPV-associated cancers.
